Compounds > pyrazines

Page last updated: 2024-08-21

pyrazines and Tumor Lysis Syndrome

pyrazines has been researched along with Tumor Lysis Syndrome in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (70.00)	29.6817
2010's	3 (30.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aiba, K; Hatake, K; Mishima, Y; Nishimura, N; Sakajiri, S; Suzuki, K; Terui, Y; Ueda, K; Yokoyama, M	1
Furtado, M; Rule, S	1
Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K	1
Bhagat, G; Bongero, D; Lipstein, M; Montanari, F; O'Connor, O; Paoluzzi, L	1
Politou, M; Rahemtulla, A; Terpos, E	1
Herrington, JD; Jaskiewicz, AD; Wong, L	1
Hönemann, D; Kenealy, MK; Prince, HM	1
Arai, A; Koyama, T; Kurosu, T; Miki, T; Miura, O; Murakami, N; Oshikawa, G; Tohda, S	1
Boral, AL; Esseltine, DL; Jakob, C; Mehta, J; Richardson, P; Sezer, O; Singhal, S; Stadtmauer, E; Vesole, DH	1
Chim, CS	1

Trials

1 trial(s) available for pyrazines and Tumor Lysis Syndrome

Article	Year
Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clinical lymphoma & myeloma, 2006, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Proliferation; Chromosome Deletion; Dexamethasone; Female; Humans; Male; Multiple Myeloma; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome	2006

Other Studies

9 other study(ies) available for pyrazines and Tumor Lysis Syndrome

Article	Year
Rapid progression of anemia related to tumor-lysis syndrome associated with bortezomib treatment in myeloma patients. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:5 Topics: Adult; Anemia; Antineoplastic Agents; Area Under Curve; beta 2-Microglobulin; Biomarkers; Boronic Acids; Bortezomib; Creatinine; Disease Progression; Female; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Multiple Myeloma; Predictive Value of Tests; Pyrazines; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Tumor Lysis Syndrome	2014
Bortezomib-associated tumor lysis syndrome in multiple myeloma. Leukemia & lymphoma, 2008, Volume: 49, Issue:12 Topics: Aged; Boronic Acids; Bortezomib; Female; Humans; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome	2008
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2010, Volume: 51, Issue:8 Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis	2010
Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:5 Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; HIV Infections; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Pyrazines; Tumor Lysis Syndrome	2010
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:10 Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Male; Multiple Myeloma; Pyrazines; Tumor Lysis Syndrome	2004
Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy, 2005, Volume: 25, Issue:12 Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Fatal Outcome; Female; Humans; Leukemia, Plasma Cell; Middle Aged; Pyrazines; Tumor Lysis Syndrome	2005
Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma. Pharmacotherapy, 2006, Volume: 26, Issue:8 Topics: Adult; Aged; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Protease Inhibitors; Pyrazines; Tumor Lysis Syndrome	2006
[Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2006, Volume: 47, Issue:8 Topics: Antineoplastic Agents; Bence Jones Protein; Biomarkers; Boronic Acids; Bortezomib; Dexamethasone; Drug Therapy, Combination; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Treatment Outcome; Tumor Lysis Syndrome	2006
Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; L-Lactate Dehydrogenase; Middle Aged; Multiple Myeloma; Pyrazines; Thalidomide; Tumor Lysis Syndrome	2008